Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Total body irradiation: current indications]

P Giraud1, S Danhier, B Dubray

  • 1Département d'oncologie-radiothérapie, Institut Curie, Paris, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|September 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate cancer brachytherapy: SFRO guidelines 2021.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same author

Occupational Radiological Protection in Brachytherapy.

Annals of the ICRP·2021
Same author

Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC.

Scientific reports·2021
Same author

[Treatment of advanced basal cell carcinoma with vismodegib followed by radiotherapy].

Annales de dermatologie et de venereologie·2020
Same author

[Construction of radiobiological models as TCP (tumor control probability) and NTCP (normal tissue complication probability): from dose to clinical effects prediction].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020
Same author

[Prophylactic nodal radiotherapy for breast cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2019
Same journal

White paper on radiotherapy in France: Ten objectives to strengthen one of the major modalities of cancer treatment.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Factors affecting the stability of deep inspiration breath-holding in radiotherapy for left-sided breast cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Radiotherapy as a curative strategy for primary pleural indolent lymphomas: Analytical guidelines based on literature and an illustrative population-based case series.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Cone-beam computed tomography-based radiomics for tumour regression assessment during radiotherapy of non-small-cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
See all related articles

Optimizing total body irradiation (TBI) schedules involves balancing tumor cell killing, engraftment, and normal tissue damage. Fractionated TBI may reduce toxicity, but requires careful consideration of graft rejection and relapse risks.

Area of Science:

  • Radiation Oncology
  • Hematopoietic Stem Cell Transplantation
  • Cancer Therapy

Context:

  • Total body irradiation (TBI) is a critical component of conditioning regimens for hematopoietic stem cell transplantation (HSCT).
  • Determining optimal TBI dose and fractionation is complex due to numerous influencing factors.
  • Clinical data interpretation is challenging due to logistic constraints and limited randomized trials.

Purpose:

  • To analyze the impact of TBI dose, fractionation, and dose rate on HSCT outcomes.
  • To provide evidence-based recommendations for adapting TBI schedules in clinical practice.
  • To compare TBI-containing regimens with chemotherapy-only alternatives.

Summary:

  • Low dose per fraction at a low dose rate protects organs at risk, suggesting fractionated TBI for toxicity reduction, especially in pediatric patients.

Related Experiment Videos

  • Fractionated TBI should be avoided with T-cell depleted transplants due to graft rejection risk; increasing dose may enhance toxicity.
  • Higher relapse rates observed with fractionated or low dose rate TBI in chronic myeloid leukemia suggest dose escalation or avoidance in certain contexts.
  • Cyclophosphamide/TBI regimens are comparable or superior to chemotherapy-only regimens like busulfan/cyclophosphamide, which serves as an alternative for patients with prior radiation exposure.

    • Impact:

    • Informs clinical decision-making for TBI in HSCT, aiming to improve patient outcomes by minimizing toxicity and relapse.
    • Highlights the trade-offs between fractionated and conventional TBI schedules regarding normal tissue damage, graft rejection, and disease relapse.
    • Supports the use of TBI-containing regimens as effective treatments for various hematologic malignancies.